06/05/23 7:00 AMNasdaq : KRYS conferenceslow floatKrystal Biotech to Present at Upcoming Investor ConferencesKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the following upcomingRHEA-AIneutral
05/22/23 7:00 AMNasdaq : KRYS low floatKrystal Biotech Announces $160 Million Private Placement Equity FinancingKrystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced that it has entered into a securities purchase agreement for theRHEA-AIneutral
05/19/23 1:57 PMNasdaq : KRYS fda approvallow floatKrystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis BullosaDystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations in the COL7A1 gene, resulting in lack of production of functional type VII collagen (COL7) protein VYJUVEK is a topical gel that addresses theRHEA-AIneutral
05/08/23 8:23 AMNasdaq : KRYS earningslow floatKrystal Biotech Announces First Quarter 2023 Financial Results and Operational HighlightsPDUFA date of May 19, 2023 Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under Compassionate Use Program Strong balance sheet, closing the quarter with $355.5 million in cash,RHEA-AIneutral
04/24/23 7:00 AMNasdaq : KRYS clinical triallow floatKrystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use ProgramData presented at Association for Research in Vision and Ophthalmology Annual Meeting on April 23, 2023 Topical application of B-VEC to the eye was well tolerated and patient showed significant improvement of visual acuity and complete corneal re-epithelization PITTSBURGH, April 24, 2023 (GLOBERHEA-AIneutral
04/13/23 7:00 AMNasdaq : KRYS conferenceslow floatKrystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual MeetingKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), aRHEA-AIneutral
03/06/23 7:00 AMNasdaq : KRYS managementlow floatKrystal Biotech Appoints Catherine Mazzacco to Board of DirectorsKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors.RHEA-AIneutral
03/02/23 7:00 AMNasdaq : KRYS conferenceslow floatKrystal Biotech to Present at the 43rd Annual TD Cowen Health Care ConferenceKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the 43rd Annual TD CowenRHEA-AIneutral
02/27/23 7:00 AMNasdaq : KRYS earningslow floatKrystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress• B-VEC PDUFA date May 19, 2023 • Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine • Four pipeline clinical trials in dermatology, respiratory and aesthetics to initiate in 2023 • Strong balance sheet, closingRHEA-AIneutral
01/18/23 7:00 AMNasdaq : KRYS low floatKrystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic FibrosisKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the European Commission has granted orphan designation forRHEA-AIvery positive